News Related to C. Difficile Infection

Related coverage linked through entity extraction aliases.

Acurx Launches Clinical Trial Program for Ibezapolstat in Recurrent C. difficile Infection

Mar 10, 2026

Acurx Pharmaceuticals announced a new clinical trial program for ibezapolstat in patients with recurrent C. difficile infection, building on Phase 2 results showing 96% clinical cure rates with no recurrence while sparing the gut microbiome.

Acurx Pharmaceuticals Schedules Q4 2025 Earnings Call for March 13

Mar 03, 2026

Acurx Pharmaceuticals will discuss full year and fourth quarter 2025 financial results on March 13, 2026, and provide updates on ibezapolstat, its lead antibiotic candidate preparing for international Phase 3 trials for C. difficile infection.